{"id":"NCT00441350","sponsor":"Menarini Group","briefTitle":"Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension","officialTitle":"Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2007-02-28","resultsPosted":"2021-07-28","lastUpdate":"2021-07-28"},"enrollment":1004,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"OM 40","otherNames":["Treatment"]},{"type":"DRUG","name":"OM/HCTZ 40/12.5","otherNames":["Treatment"]}],"arms":[{"label":"OM 40","type":"ACTIVE_COMPARATOR"},{"label":"OM/HCTZ 40/12.5","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to assess the anti-hypertensive effect of OM/HCTZ 40/12.5 mg combination therapy compared to OM 40 mg monotherapy in lowering sitting diastolic BP in hypertensive patients after 8 weeks of double-blind treatment.\n\nThe study consisted of two sequential phases of 8 weeks duration each:\n\nDuring the first phase, OM 40 mg monotherapy was compared with OM/HCTZ 40/12.5 mg in order to evaluate the additional benefit of OM/HCTZ 40/12.5 mg in the treatment of essential moderate to severe hypertension.\n\nDuring the second phase, patients whose BP proved to be insufficiently controlled by the OM 40 mg monotherapy were to start OM/HCTZ 40/12.5 mg combination therapy while patients whose BP proved to be insufficiently controlled by the OM/HCTZ 40/12.5 mg combination were to be up-titrated to the OM/HCTZ 40/25 mg combination to evaluate the additional benefit of the up-titrated combination.\n\nThe study was be conducted by qualified and experienced personnel with adherence to GCP, current guidelines on the design of studies in hypertension, the applicable regulatory requirements and the ethical principles based on the Declaration of Helsinki.","primaryOutcome":{"measure":"dBP Change After 8 Weeks Phase A","timeFrame":"Eight weeks","effectByArm":[{"arm":"OM 40","deltaMin":-15.8,"sd":9.71},{"arm":"OM/HCTZ 40/12.5","deltaMin":-18.9,"sd":9.32}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":65,"countries":["Croatia","Czechia","Denmark","Germany","Israel","Italy","Poland","Romania"]},"refs":{"pmids":["20593911"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":188},"commonTop":["Nasopharyngitis","Headache","Bronchitis","Dizziness","Cough"]}}